UNSPSC 51262906: Procinolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLJ0HIL21J. European Medicines Agency schedules Procinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10060MIG. Procinolol generally arises in the molecular formula C15H23NO2.

UNSPSC 51262906 Procinolol is a Commodity code covering pharmaceutical products, though recent state and local solicitations under this code show a divergence: state and local governments are actually procuring naloxone and drug deactivation systems, not procinolol specifically. Seminole County, Florida is seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to a county health facility; Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations. The issuing bodies span county health departments and state human services agencies, each pursuing pharmaceutical or pharmacy-benefit procurement through different mechanisms—sealed competitive bidding for discrete product purchases and exploratory market research for systemic pharmacy program restructuring.

Activity under this code appears concentrated in the South, with documented recent solicitations from Florida and Texas. Seminole County's IFB 60459723LAS closed July 26, 2023, and required vendors to submit unit pricing electronically with drug-free workplace and E-Verify compliance; the contract offered an initial two-year term with an optional one-year renewal and included probationary termination rights for the county. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, is preliminary market research rather than a formal solicitation—it seeks vendor responses on direct contracting capacity, pricing-model flexibility, and implementation strategy without committed budget, timeline, or award value. Neither opportunity specifies set-aside designations. The mismatch between the code name (procinolol, a beta-blocker cardiovascular medication) and the actual procurements (naloxone for overdose response and pharmacy-benefit restructuring) suggests this code may carry misaligned tagging or sees limited relevant activity under its nominal pharmaceutical scope.